Literature DB >> 3938101

Effects of challenge dose on the clinical and immune responses of cattle vaccinated with reduced doses of Brucella abortus strain 19.

A W Confer, S M Hall, C B Faulkner, B H Espe, B L Deyoe, R J Morton, R A Smith.   

Abstract

Fifty-seven pregnant beef heifers that were unvaccinated or previously vaccinated with Brucella abortus S19, at a dose of either 10(9) or 10(10) colony-forming units (CFU), were challenge-exposed intraconjunctivally with virulent B. abortus S2308 at a dose of 9.4 X 10(6) CFU (Experiment 1) or 5.2 X 10(7) CFU (Experiment 2). In Experiment 1, S19 afforded significant protection (P less than 0.01) against challenge exposure in that 8 of 9 unvaccinated heifers, 1 of 11 vaccinated with 10(9) CFU, and 3 of 10 vaccinated with 10(10) CFU aborted or delivered weak, non-viable calves. In Experiment 2, vaccination did not afford significant protection (P greater than 0.05) in that 9 of 9 unvaccinated heifers, 8 of 10 vaccinated with 10(9) CFU, and 8 of 8 vaccinated with 10(10) CFU aborted. Serologic responses to B. abortus were determined by three standard tests, as well as a quantitative fluorometric immunoassay (FIAX) and an enzyme-linked immunosorbent assay. In Experiment 1, the early serologic response, 0-8 weeks after challenge, appeared greater for controls than for vaccinates, but in Experiment 2, the early response, 0-6 weeks after challenge exposure, appeared greater for vaccinates than for controls. The lymphocyte blast transformation assay, using heat-killed B. abortus as an antigen, was performed sequentially after challenge exposure. In general, mean responses were significantly higher (P less than 0.05) for vaccinated than for non-vaccinated heifers. For individual heifers, an association could not be established between the lymphocyte blast transformation assay and the clinical response to challenge exposure.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3938101     DOI: 10.1016/0378-1135(85)90065-3

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  7 in total

Review 1.  Alternative strategies for vaccination to brucellosis.

Authors:  David W Pascual; Xinghong Yang; Hongbin Wang; Zakia Goodwin; Carol Hoffman; Beata Clapp
Journal:  Microbes Infect       Date:  2017-12-26       Impact factor: 2.700

2.  Comparative study on responses of cattle and water buffalo (Bubalus bubalis) to experimental inoculation of Brucella abortus biovar 1 by the intraconjunctival route--a preliminary report.

Authors:  Abiodun A Adesiyun; Geoff T Fosgate; Anil Persad; Mervyn Campbell; Ravi Seebaransingh; Alva Stewart-Johnson
Journal:  Trop Anim Health Prod       Date:  2010-07-08       Impact factor: 1.559

3.  Comparison of abortion and infection after experimental challenge of pregnant bison and cattle with Brucella abortus strain 2308.

Authors:  S C Olsen; C Johnson
Journal:  Clin Vaccine Immunol       Date:  2011-10-05

4.  Comparison of TRACK XI fluorometric immunoassay system with other serologic tests for detection of serum antibody to Brucella abortus in cattle.

Authors:  S M Hall; A W Confer
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

5.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

6.  Immune Response of Calves Vaccinated with Brucella abortus S19 or RB51 and Revaccinated with RB51.

Authors:  Elaine M S Dorneles; Graciela K Lima; Andréa Teixeira-Carvalho; Márcio S S Araújo; Olindo A Martins-Filho; Nammalwar Sriranganathan; Hamzeh Al Qublan; Marcos B Heinemann; Andrey P Lage
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

7.  Registered Influenza Viral Vector Based Brucella abortus Vaccine for Cattle in Kazakhstan: Age-Wise Safety and Efficacy Studies.

Authors:  Sholpan Ryskeldinova; Nadezhda Zinina; Zhailaubay Kydyrbayev; Bolat Yespembetov; Yerken Kozhamkulov; Dulat Inkarbekov; Nurika Assanzhanova; Aigerim Mailybayeva; Dina Bugybayeva; Makhpal Sarmykova; Berik Khairullin; Kairat Tabynov; Aitbay Bulashev; Batyrbek Aitzhanov; Khairulla Abeuov; Abylay Sansyzbay; Tlektes Yespolov; Gourapura J Renukaradhya; Steven Olsen; Angel Oñate; Kaissar Tabynov
Journal:  Front Cell Infect Microbiol       Date:  2021-07-01       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.